Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
NDA filed with FDA for nanoparticle-based Abraxane
April 6th, 2004
American Pharmaceutical Partners, Inc., (APP, APPX) and American BioScience, Inc., (ABI) announced that ABI has completed the filing of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Abraxane, for the treatment of metastatic breast cancer. Using proprietary nanoparticle technology, Abraxane combines the active drug paclitaxel with a natural protein called albumin into a nanoparticle 1/100th the size of a red blood cell, avoiding the need for any solvent. Abraxane is the first solvent-free nanoparticle albumin-bound chemotherapeutic, and may potentially exploit an inherent pathway for albumin receptor-mediated transport of drugs across...
Source: Cancer Weekly (2004-04-06)
|
